Table 3.
Risk stratification of AML according To 2017 ELN recommendations [24]
| Risk profiles | Subgroups |
|---|---|
| Favorable | t(8;21)(q22;q22.1); RUNX1-RUNX1T1 |
| inv (16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | |
| Mutated NPM1 without FLT3-ITD | |
| Mutated NPM1 with FLT3-ITDlow | |
| Biallelic mutated CEBPA | |
| Intermediate | Mutated NPM1 and FLT3-ITDhigh |
| Wild-type NPM1 without FLT3-ITD | |
| Wild-type NPM1 with FLT3-ITDlow | |
| t(9;11)(p21.3;q23.3); MLLT3-KMT2A | |
| Cytogenetic abnormalities not classified | |
| Adverse | t(6;9)(p23;q34.1); DEK-NUP214 |
| t(v;11q23.3); KMT2A rearranged | |
| t(9;22)(q34.1;q11.2); BCR-ABL1 | |
| inv (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) | |
| Complex karyotype, monosomal karyotype | |
| -5 or del(5q); −7; −17/abn(17p) | |
| Wild-type NPM1 and FLT3-ITDhigh | |
| Mutated RUNX1 | |
| Mutated ASXL1 | |
| Mutated TP53 |
Low, low allelic ratio (< 0.5); high, high allelic ratio (≥0.5)